Hema Now
In this episode of Hema Now, Robert Negrin, President of the American Society of Hematology (ASH), reflects on his distinguished career in stem cell transplantation and cellular therapy, and shares his vision for the future of the field. From shaping global haematology priorities to advancing innovative treatments such as CAR-T cell therapy, he explores both the remarkable progress and the ongoing challenges facing clinicians and researchers today. The conversation also highlights the importance of translational research, mentorship, and collaboration in driving meaningful improvements in patient care, while looking ahead to the technologies and breakthroughs that could redefine haematology in the years to come.
Spotify | Apple | Amazon Music | YouTube | Download MP3 (34 mins)
Robert Negrin is President of the American Society of Hematology (ASH) and Professor of Medicine at Stanford University, California, USA, where he was also former Chief of the Division of Blood and Marrow Transplantation and Cellular Therapy. A physician–scientist with decades of leadership in the field, Negrin’s work has helped advance our understanding of immune regulation following stem cell transplantation and the development of cellular therapies for haematologic diseases.
Timestamps:
00:00 – Introduction
00:49 – Career inspiration
04:40 – Prophylaxis turning points
09:41 – Key care advances
12:12 – Current research questions
15:00 – Joint risk factors
19:10 – Emerging therapies impact
24:24 – Recognising joint pain
26:08 – Gaps in care
29:11 – Future priorities
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Disclosure: TBC
Keywords: American Society of Hematology (ASH), CAR-T cell therapy, cellular therapy, haematology, immune therapy, mentorship, stem cell transplantation, translational research.
